Monkeypox future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
==Future or investigational therapies== | ==Future or investigational therapies== | ||
*Countries are developing policies to define high risk groups to receive vaccines. Clinical investigations will be running to evaluate the appropriateness of vaccination to contain the outbreak<ref name="urlMonkeypox">{{cite web |url=https://www.who.int/news-room/fact-sheets/detail/monkeypox |title=Monkeypox |format= |work= |accessdate=2022-06-16}}</ref>. | *Countries are developing policies to define high risk groups to receive vaccines. Clinical investigations will be running to evaluate the appropriateness of vaccination to contain the outbreak<ref name="urlMonkeypox">{{cite web |url=https://www.who.int/news-room/fact-sheets/detail/monkeypox |title=Monkeypox |format= |work= |accessdate=2022-06-16}}</ref>. | ||
*Antiviral agents such as Cidofovir or Tecovirimat were evaluated only for safety but not efficacy on human models. Future trials may evaluate the drug’s effectiveness to treat humans cases of monkeypox<ref name="pmid12076747">{{cite journal| author=De Clercq E| title=Cidofovir in the treatment of poxvirus infections. | journal=Antiviral Res | year= 2002 | volume= 55 | issue= 1 | pages= 1-13 | pmid=12076747 | doi=10.1016/s0166-3542(02)00008-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12076747 }} </ref><ref name="pmid18316519">{{cite journal| author=Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J | display-authors=etal| title=Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. | journal=Antimicrob Agents Chemother | year= 2008 | volume= 52 | issue= 5 | pages= 1721-7 | pmid=18316519 | doi=10.1128/AAC.01303-07 | pmc=2346641 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18316519 }} </ref><ref name="pmid22777041">{{cite journal| author=Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF | display-authors=etal| title=Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. | journal=Antimicrob Agents Chemother | year= 2012 | volume= 56 | issue= 9 | pages= 4900-5 | pmid=22777041 | doi=10.1128/AAC.00904-12 | pmc=3421894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22777041 }} </ref>. | *Antiviral agents such as Cidofovir or Tecovirimat were evaluated only for safety but not efficacy on human models. Future trials may evaluate the drug’s effectiveness to treat humans cases of monkeypox<ref name="pmid12076747">{{cite journal| author=De Clercq E| title=Cidofovir in the treatment of poxvirus infections. | journal=Antiviral Res | year= 2002 | volume= 55 | issue= 1 | pages= 1-13 | pmid=12076747 | doi=10.1016/s0166-3542(02)00008-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12076747 }} </ref><ref name="pmid18316519">{{cite journal| author=Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J | display-authors=etal| title=Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. | journal=Antimicrob Agents Chemother | year= 2008 | volume= 52 | issue= 5 | pages= 1721-7 | pmid=18316519 | doi=10.1128/AAC.01303-07 | pmc=2346641 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18316519 }} </ref><ref name="pmid22777041">{{cite journal| author=Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF | display-authors=etal| title=Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. | journal=Antimicrob Agents Chemother | year= 2012 | volume= 56 | issue= 9 | pages= 4900-5 | pmid=22777041 | doi=10.1128/AAC.00904-12 | pmc=3421894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22777041 }} </ref>. | ||
*In 2022, most cases in non-endemic areas no travel association to endemic areas and were among men who have sex with men. It is hypothesized that monkeypox can be a sexuality transmitted | *In 2022, most cases in non-endemic areas had no travel association to endemic areas and were among men who have sex with men. It is hypothesized that monkeypox can be a sexuality transmitted<ref name="pmid35692117">{{cite journal |vauthors=Bragazzi NL, Kong JD, Mahroum N, Tsigalou C, Khamisy-Farah R, Converti M, Wu J |title=Epidemiological trends and clinical features of the ongoing monkeypox epidemic: a preliminary pooled data analysis and literature review |journal=[[Journal of Medical Virology]] |volume= |issue= |pages= |date=June 2022 |pmid=35692117 |doi=10.1002/jmv.27931 |url= |accessdate=2022-06-16}}</ref><ref name="pmid">{{cite journal |vauthors=Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM |title=Clinical features and management of human monkeypox: a retrospective observational study in the UK |journal=[[]] |volume= |issue= |pages= |date=May 2022 |pmid= |doi=10.1016/S1473-3099(22)00228-6 |url= |accessdate=2022-06-15}}</ref>. The role of semen and vaginal fluids in the transmission of monkeypox is being investigated<ref name="urlU.S. Monkeypox Outbreak 2022: Situation Summary | Monkeypox | Poxvirus | CDC">{{cite web |url=https://www.cdc.gov/poxvirus/monkeypox/response/2022/index.html |title=U.S. Monkeypox Outbreak 2022: Situation Summary | Monkeypox | Poxvirus | CDC |format= |work= |accessdate=}}</ref>. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 22:28, 16 June 2022
|
Monkeypox Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Monkeypox future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Monkeypox future or investigational therapies |
|
Risk calculators and risk factors for Monkeypox future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Bassel Almarie M.D.[2]
Overview
Countries are developing policies to define high risk groups to receive vaccines. Clinical investigations will be running to evaluate the appropriateness of vaccination to contain the outbreak[1].
Future or investigational therapies
- Countries are developing policies to define high risk groups to receive vaccines. Clinical investigations will be running to evaluate the appropriateness of vaccination to contain the outbreak[1].
- Antiviral agents such as Cidofovir or Tecovirimat were evaluated only for safety but not efficacy on human models. Future trials may evaluate the drug’s effectiveness to treat humans cases of monkeypox[2][3][4].
- In 2022, most cases in non-endemic areas had no travel association to endemic areas and were among men who have sex with men. It is hypothesized that monkeypox can be a sexuality transmitted[5][6]. The role of semen and vaginal fluids in the transmission of monkeypox is being investigated[7].
References
- ↑ 1.0 1.1 "Monkeypox". Retrieved 2022-06-16.
- ↑ De Clercq E (2002). "Cidofovir in the treatment of poxvirus infections". Antiviral Res. 55 (1): 1–13. doi:10.1016/s0166-3542(02)00008-6. PMID 12076747.
- ↑ Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J; et al. (2008). "Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor". Antimicrob Agents Chemother. 52 (5): 1721–7. doi:10.1128/AAC.01303-07. PMC 2346641. PMID 18316519.
- ↑ Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF; et al. (2012). "Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers". Antimicrob Agents Chemother. 56 (9): 4900–5. doi:10.1128/AAC.00904-12. PMC 3421894. PMID 22777041.
- ↑ Bragazzi NL, Kong JD, Mahroum N, Tsigalou C, Khamisy-Farah R, Converti M, Wu J (June 2022). "Epidemiological trends and clinical features of the ongoing monkeypox epidemic: a preliminary pooled data analysis and literature review". Journal of Medical Virology. doi:10.1002/jmv.27931. PMID 35692117 Check
|pmid=value (help).|access-date=requires|url=(help) - ↑ Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM (May 2022). "Clinical features and management of human monkeypox: a retrospective observational study in the UK". [[]]. doi:10.1016/S1473-3099(22)00228-6.
|access-date=requires|url=(help) - ↑ "U.S. Monkeypox Outbreak 2022: Situation Summary | Monkeypox | Poxvirus | CDC".